Literature DB >> 27270303

Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression.

Rachel L Soon1, Justin R Lenhard1, Irene Reilly1, Tanya Brown1, Alan Forrest1, Brian T Tsuji1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27270303     DOI： 10.1038/ja.2016.59

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  15 in total

1.  Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Authors:  Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

Review 2.  Molecular mechanisms of agr quorum sensing in virulent staphylococci.

Authors:  Elizabeth A George; Tom W Muir
Journal:  Chembiochem       Date:  2007-05-25       Impact factor: 3.164

3.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

Authors:  Richard G Wunderink; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Mark J Kunkel; Alice Baruch; William T McGee; Arlene Reisman; Jean Chastre
Journal:  Clin Infect Dis       Date:  2012-01-12       Impact factor: 9.079

4.  Vancomycin concentrations in infected and noninfected human bone.

Authors:  A L Graziani; L A Lawson; G A Gibson; M A Steinberg; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Penetration of vancomycin into human lung tissue.

Authors:  M Cruciani; G Gatti; L Lazzarini; G Furlan; G Broccali; M Malena; C Franchini; E Concia
Journal:  J Antimicrob Chemother       Date:  1996-11       Impact factor: 5.790

6.  Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Authors:  Justin R Lenhard; Tanya Brown; Michael J Rybak; Calvin J Meaney; Nicholas B Norgard; Zackery P Bulman; Daniel A Brazeau; Steven R Gill; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

8.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

Review 9.  Linezolid: effectiveness and safety for approved and off-label indications.

Authors:  Konstantinos Z Vardakas; Fotinie Ntziora; Matthew E Falagas
Journal:  Expert Opin Pharmacother       Date:  2007-10       Impact factor: 3.889

10.  Impact of accessory gene regulator (agr) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus.

Authors:  Brian T Tsuji; Robert D MacLean; Linda D Dresser; Martin J McGavin; Andrew E Simor
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-05-20       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.